| Income Statement | 2026-06-30 | |||
|---|---|---|---|---|
| Currency translation (loss) gain | -22 | |||
| Other comprehensive (loss) income, net of tax | -22 | |||
| Series BNon Voting Convertible Preferred Stock | -6,441 | |||
| Series CNon Voting Convertible Preferred Stock | -678 | |||
| Common Stock | -24,055 | |||
| Net loss | -31,174 | |||
| Total comprehensive loss | -31,196 | |||
| Basic EPS | -393.59 | |||
| Diluted EPS | -393.59 | |||
| Basic Average Shares | 16,366 | |||
| Diluted Average Shares | 16,366 | |||
Damora Therapeutics, Inc. (DMRA)
Damora Therapeutics, Inc. (DMRA)